LS60 Stock Chart & Stats
€0.59
<€0.01(0.74%)
At close: 4:00 PM EST
€0.59
<€0.01(0.74%)
Day’s Range― - ―
52-Week Range€0.23 - €1.16
Previous CloseN/A
Volume0.00
Average Volume (3M)75.00
Market Cap
€9.74M
Enterprise Value€79.44M
Total Cash (Recent Filing)€13.04M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-0.03
Next Earnings
Aug 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.20
Shares Outstanding31,163,593
10 Day Avg. Volume175
30 Day Avg. Volume75
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.55
Price to Sales (P/S)10.18
P/FCF Ratio-4.96
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)€3.49M
Bulls Say, Bears Say
Bulls Say
Installed-base Recurring RevenueCLS's business model includes recurring sales of disposables and service after capital sale. That installed-base dynamic creates a durable revenue tier: once systems are placed, repeat procedure consumables and maintenance generate predictable, high-frequency revenue over months, supporting long-term margin recovery if adoption grows.
Low Financial LeverageThe company carries virtually no debt and meaningful equity, reducing financing risk and interest burden. This stronger capital structure provides a durable cushion to fund near-term operations or strategic initiatives, extending runway and lowering insolvency risk while management works to return to cash generation.
Niche, Minimally Invasive Medical TechCLS focuses on image-guided minimally invasive laserthermia for soft-tissue tumors, aligning with structural healthcare trends favoring less invasive procedures. This clinical positioning and integration with imaging systems can sustain durable demand and create barriers to entry if clinical outcomes and hospital workflows validate the technology.
Bears Say
Shrinking RevenueSustained top-line contraction undermines the commercial flywheel: fewer installed systems and reduced procedure volumes limit recurring consumable sales and service revenue. Continued revenue shrinkage over multiple periods reduces ability to achieve scale economies and delays pathways to durable profitability.
Negative Gross Margins And LossesNegative gross margins indicate structural pricing or cost issues at the product level, not just temporary expense timing. Deep operating and net losses relative to revenue mean the business model has yet to reach sustainable unit economics, requiring material improvement in pricing, mix, or cost structure to persistently generate profits.
Persistent Cash BurnConsistent negative operating and free cash flow (TTM -34.8M) forces reliance on external financing or equity dilution to fund operations. Even with low debt, ongoing cash consumption constrains investment in commercialization and R&D, and creates medium-term execution risk if revenue does not reverse and cash reserves dwindle.
LS60 FAQ
What was Clinical Laserthermia Systems AB Class B’s price range in the past 12 months?
Clinical Laserthermia Systems AB Class B lowest stock price was €0.23 and its highest was €1.16 in the past 12 months.
What is Clinical Laserthermia Systems AB Class B’s market cap?
Clinical Laserthermia Systems AB Class B’s market cap is €9.74M.
When is Clinical Laserthermia Systems AB Class B’s upcoming earnings report date?
Clinical Laserthermia Systems AB Class B’s upcoming earnings report date is Aug 14, 2026 which is in 38 days.
How were Clinical Laserthermia Systems AB Class B’s earnings last quarter?
Clinical Laserthermia Systems AB Class B released its earnings results on May 12, 2026. The company reported -€0.021 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.021.
Is Clinical Laserthermia Systems AB Class B overvalued?
According to Wall Street analysts Clinical Laserthermia Systems AB Class B’s price is currently Overvalued.
Does Clinical Laserthermia Systems AB Class B pay dividends?
Clinical Laserthermia Systems AB Class B does not currently pay dividends.
What is Clinical Laserthermia Systems AB Class B’s EPS estimate?
Clinical Laserthermia Systems AB Class B’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Clinical Laserthermia Systems AB Class B have?
Clinical Laserthermia Systems AB Class B has 31,163,593 shares outstanding.
What happened to Clinical Laserthermia Systems AB Class B’s price movement after its last earnings report?
Clinical Laserthermia Systems AB Class B reported an EPS of -€0.021 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 64.835%.
Which hedge fund is a major shareholder of Clinical Laserthermia Systems AB Class B?
Currently, no hedge funds are holding shares in DE:LS60
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Clinical Laserthermia Systems AB Class B
Clinical Laserthermia Systems AB (publ) engages in the development of treatment tools for diseased tissue under the TRANBERG brand in Sweden. It offers TRANBERG, a thermal therapy system designed to deliver laser energy to heat the target tissue. The company also provides mobile laser unit, a controlling component with a wavelength of 1064 nanometers that provides multiple options to control treatment. In addition, it offers various gauge laser applicators and introducers, as well as provides temperature and treatment monitoring devices. Clinical Laserthermia Systems AB (publ) was incorporated in 2006 and is headquartered in Lund, Sweden.
Technical Analysis
SpectraCure AB
―
Luxbright AB
―
Scandinavian Real Heart AB
―
Nosa Plugs AB
―
Arcoma AB
―